Clinical Trials Browser

Phase 1/2 × NIH × oblimersen × Clear all

NCT00064259 2021-02-17

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

Phase 1/2 Terminated

15 enrolled 5 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT00063934 2019-03-05

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

31 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00062244 2013-06-04

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Phase 1/2 Completed

Waldenstrom Macroglobulinemia

NCT00086944 2013-01-24

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Phase 1/2 Completed

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell